scholarly journals Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up

2014 ◽  
Vol 28 (5) ◽  
pp. 662-669 ◽  
Author(s):  
Melinda E Sanders ◽  
Peggy A Schuyler ◽  
Jean F Simpson ◽  
David L Page ◽  
William D Dupont
Keyword(s):  
Local Recurrence ◽  
Natural History ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Low Grade ◽  
History Of

scholarly journals Modeling the natural history of ductal carcinoma in situ based on population data

2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Sarocha Chootipongchaivat ◽  
Nicolien T. van Ravesteyn ◽  
Xiaoxue Li ◽  
Hui Huang ◽  
Harald Weedon-Fekjær ◽  
...  
Keyword(s):  
Natural History ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Population Data ◽  
History Of

The natural history of ductal carcinoma in situ of the breast: a review

2005 ◽  
Vol 97 (2) ◽  
pp. 135-144 ◽  
Author(s):  
Bircan Erbas ◽  
Elena Provenzano ◽  
Jane Armes ◽  
Dorota Gertig
Keyword(s):  
Natural History ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
History Of

Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: A comparative study with long follow-up

1998 ◽  
Vol 29 (9) ◽  
pp. 915-923 ◽  
Author(s):  
Sunil Badve ◽  
Roger P A'hern ◽  
Ann M Ward ◽  
Rosemary R Millis ◽  
Sarah E Pinder ◽  
...  
Keyword(s):  
Local Recurrence ◽  
Comparative Study ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma

Ductal Carcinoma In Situ and Progression to Invasive Cancer: A Review of the Evidence

2021 ◽  
Author(s):  
Samantha L Heller ◽  
Anastasia Plaunova ◽  
Yiming Gao
Keyword(s):  
Breast Cancer ◽  
Natural History ◽  
Ductal Carcinoma In Situ ◽  
Biopsy Specimen ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Population Based ◽  
History Of ◽  
Patient Prognosis

Abstract Ductal carcinoma in situ (DCIS), breast cancer confined to the milk ducts, is a heterogeneous entity. The question of how and when a case of DCIS will extend beyond the ducts to become invasive breast cancer has implications for both patient prognosis and optimal treatment approaches. The natural history of DCIS has been explored through a variety of methods, from mouse models to biopsy specimen reviews to population-based screening data to modeling studies. This article will review the available evidence regarding progression pathways and will also summarize current trials designed to assess DCIS progression.

scholarly journals Low-grade ductal carcinoma in situ (DCIS) arising in a fibroadenoma of the breast during 5 years follow-up

Medicine ◽  
2021 ◽  
Vol 100 (10) ◽  
pp. e24023
Author(s):  
Hiroko Shojaku ◽  
Ryota Hori ◽  
Toru Yoshida ◽  
Kazuhiro Matsui ◽  
Katsuo Shimada ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Low Grade

scholarly journals Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery

2018 ◽  
Vol 142 (9) ◽  
pp. 1120-1126 ◽  
Author(s):  
Mirna B. Podoll ◽  
Emily S. Reisenbichler ◽  
Lania Roland ◽  
Andrew Bruner ◽  
Sarah Mizuguchi ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Low Risk ◽  
Low Grade ◽  
Core Needle

Context.— Ductal carcinoma in situ (DCIS) represents 20% of screen-detected breast cancers. The likelihood that certain types of DCIS are slow growing and may never progress to invasion suggests that our current standards of treating DCIS could result in overtreatment. The LORIS (LOw RISk DCIS) and LORD (LOw Risk DCIS) trials address these concerns by randomizing patients with low-risk DCIS to either active surveillance or conventional treatment. Objective.— To determine the upgrade rate of DCIS diagnosed on core needle biopsy to invasive carcinoma at surgery and to evaluate the safety of managing low-risk DCIS with surveillance alone, by characterizing the pathologic and clinical features of upgraded cases and applying criteria of the LORD and LORIS trials to these cases. Design.— A 10-year retrospective analysis of DCIS on core needle biopsy with subsequent surgery. Results.— We identified 1271 cases of DCIS on core needle biopsy: 200 (16%) low grade, 649 (51%) intermediate grade, and 422 (33%) high grade. Of the 1271 cases, we found an 8% upgrade rate to invasive carcinoma (n = 105). Nineteen of the 105 upgraded cases (18%) had positive lymph nodes. Low-grade DCIS was least likely to upgrade to invasion, comprising 10% (10 of 105) of upgraded cases. Three of the 105 upgraded cases (3%) met criteria for the LORD trial, and all were low-grade DCIS on core needle biopsy with favorable biology on follow-up. Conclusions.— There is a clear risk of upgrade to invasion on follow-up excision; however, applying strict criteria of the LORD trial effectively decreases the likelihood of a missed invasive component or missed aggressive pathologic features.

Sign in / Sign up

Export Citation Format

Share Document